Invasive Breast Cancer, Breast Cancer Mortality Increased Long Term After DCIS
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 25, 2024 -- Women with non-screen-detected ductal carcinoma in situ have an increased risk for invasive breast cancer and breast cancer death, according to a study published online Jan. 24 in The BMJ.
Gurdeep S. Mannu, M.B.B.S., D.Phil., from the University of Oxford in the United Kingdom, and colleagues examined the long-term risks for invasive cancer and death related to breast cancer after non-screen-detected ductal carcinoma in situ among 27,543 women in England who were diagnosed during 1990 to 2018, outside the National Health Service breast screening program.
The researchers found that by Dec. 31, 2018, 3,651 women with non-screen-detected ductal carcinoma in situ had developed invasive breast cancer (ratio of observed to expected rate, 4.21). Throughout follow-up, the ratio of observed to expected rate of developing invasive breast cancer remained elevated among women aged younger than 45 to 70 years. The 25-year cumulative risks for invasive breast cancer were 27.3, 25.2, 21.7, and 20.8 percent for those with a diagnosis of ductal carcinoma in situ at age younger than 45, 45 to 49, 50 to 59, and 60 to 70 years, respectively. Overall, 908 women died of breast cancer (ratio of observed to expected rate, 3.83); the ratio remained elevated throughout follow-up. The 25-year cumulative risks for breast cancer death were 7.6, 5.8, 5.9, and 6.2 percent, respectively, by age at diagnosis.
"These findings should inform considerations regarding the frequency and duration of surveillance following a diagnosis of ductal carcinoma in situ, particularly for women diagnosed at younger ages," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
Donepezil Not Beneficial for Cognitive Impairment in Breast Cancer Survivors
FRIDAY, May 24, 2024 -- A once-daily dose of donepezil does not improve cognitive function among breast cancer survivors exposed to chemotherapy one to five years earlier...
ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy
THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a...
4-Dimensional Model Can Predict Lymph Node Metastases in Breast Cancer
THURSDAY, May 23, 2024 -- A deep learning model using tumor dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has high sensitivity for identifying lymph node...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.